Pharmaceuticals and diagnostics businesses are growing; exchange rates are affecting reported consolidated revenue
Roche increases sales by six per cent in the first nine months of 2026
Thursday, 22. October 2026
| Redaktion
Share on:
Roche Headquarters
Roche Headquarters, Photo: Roche

Roche increased its consolidated sales to CHF 46.49 billion between January and September 2026. Compared with the same period last year, this represents currency-adjusted growth of six per cent. In Swiss francs, growth was lower at one per cent, as the appreciation of the Swiss franc, particularly against the US dollar, weighed on reported revenue. In the third quarter, the company achieved sales growth of seven per cent at constant exchange rates and eight per cent in Swiss francs. According to the company, demand for medicines to treat serious diseases and for diagnostic solutions remained a key driver of growth.

Roche reports sales growth in its pharmaceuticals business

In the first nine months, the Pharmaceuticals division generated sales of CHF 36.21 billion. This corresponds to growth of seven per cent at constant exchange rates and two per cent in Swiss francs. Demand for medicines to treat chronic urticaria, food allergies, haemophilia A, multiple sclerosis, breast cancer and serious eye conditions contributed particularly to this performance. Together, the company’s five top-performing growth drivers generated revenue of CHF 16.8 billion. Compared with the same period last year, this represents a currency-adjusted increase of 12 per cent. At the same time, sales of medicines whose patent protection has already expired continued to decline. Here, the decline amounted to CHF 0.4 billion at constant exchange rates, or CHF 0.6 billion in the reporting currency.

Sales in the diagnostics business rose by four per cent to CHF 10.28 billion. In the reporting currency, they were on a par with the previous year. In particular, there was stronger demand for solutions for central laboratories and pathology. This enabled the company to more than offset the impact of price reforms in the Chinese healthcare sector.

Regional performance shows marked differences

Roche’s pharmaceuticals business in Japan recorded a currency-adjusted increase in sales of 25 per cent to CHF 2.35 billion. In addition to higher demand for medicines to treat blood cancer, haemophilia A, Duchenne muscular dystrophy and severe eye diseases, product deliveries to third parties and effects from the introduction of a new ERP system last year contributed to this growth. In the US, sales rose by five per cent at constant exchange rates to CHF 18.71 billion. In the European market, sales increased by two per cent to CHF 6.82 billion. The International region recorded growth of ten per cent to CHF 8.33 billion. In China, pharmaceutical sales remained stable at constant exchange rates and in Swiss francs.

The Diagnostics division also performed differently across regions. Sales in North America rose by nine per cent at constant exchange rates, driven by strong demand in the areas of central laboratory, pathology and molecular diagnostics. In Europe, the Middle East and Africa, growth stood at three per cent. Products for clinical chemistry and immunodiagnostics made a particularly significant contribution to this. In Latin America, sales rose by twelve per cent. By contrast, revenue in the Asia-Pacific region fell by four per cent. The company cites price reforms in the Chinese healthcare sector as the main cause.

Roche drives forward clinical development

In addition to its business performance, Roche reports on progress in the development of new medicines. According to Group CEO Thomas Schinecker, five further potential medicines have been moved into the final phase of clinical development this year. The company aims to bring up to 20 new medicines to market by 2030. Schinecker also referred to accelerated approval procedures by the US Food and Drug Administration (FDA). These include a compound for the treatment of both relapsing-remitting and primary progressive multiple sclerosis. Another compound for the treatment of early-stage and advanced breast cancer is also undergoing accelerated review. Should approval be granted, the company states that it is preparing for a potential market launch as early as 2026. These regulatory advances form part of the development strategy through which Roche aims to expand its portfolio of medicines.

Diagnostics and production capacities are being expanded

In the diagnostics sector, Roche received approval from the US FDA for a blood test that uses a single biomarker to aid in the detection of amyloid pathology associated with Alzheimer’s disease. The test is intended for use in both primary care and specialist medical facilities. The approval expands the company’s diagnostic portfolio in the field of neurodegenerative diseases. At the same time, Roche is investing in the expansion of its production, research and development capacities. Among the projects mentioned is a facility for injectable medicines and delivery systems in Hillsboro, USA. An innovation centre for cardiovascular, renal and metabolic diseases is being established in Boston. Furthermore, the Group is expanding its production capacities for synthetic molecules at its Basel site in Switzerland. Through these projects, the pharmaceutical company is expanding its infrastructure for the development and manufacture of medicines.

Roche confirms outlook for the full year 2026

For the full year 2026, Roche continues to expect group sales to rise by a mid-single-digit percentage at constant exchange rates. The group also intends to increase the dividend in Swiss francs once again. The performance over the first nine months shows that currency-adjusted growth was driven primarily by the pharmaceuticals business. Whilst the Pharmaceuticals division grew by seven per cent, sales in the Diagnostics division improved by four per cent. Group growth accelerated to seven per cent at constant exchange rates in the third quarter. At the same time, exchange rates have recently had a less negative impact. Based on this, Roche is sticking to its forecast for the full year.

This could interest you

Dr. Thomas Schinecker, CEO Roche Group
CEO Severin Schwan expects a low-single-digit decline in Group sales in 2023 due to further declining demand for Covid-19 products
Research & Development at Roche
Roche Headquarters
Roche Headquarters
Roche Headquarters